Uday Popat, MD, presented data from a clinical trial that indicated the fractionation of busulfan reduced toxicities among patients with AML and MDS. This data was presented at the 2023 ASCO annual meeting.
Uday Popat, MD, presented data from a clinical trial that indicated the fractionation of busulfan reduced toxicities among patients with AML and MDS. This data was presented at the 2023 ASCO annual meeting.
Uday Popat, MD, presented data...